KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 89 filers reported holding KALA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 5.28 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $7,000 | -12.5% | 29,800 | +10.0% | 0.00% | 0.0% |
| Q2 2022 | $8,000 | -74.2% | 27,100 | +19.4% | 0.00% | -66.7% |
| Q1 2022 | $31,000 | +55.0% | 22,700 | +37.6% | 0.00% | +50.0% |
| Q4 2021 | $20,000 | -82.3% | 16,500 | -61.6% | 0.00% | -77.8% |
| Q3 2021 | $113,000 | -30.2% | 42,996 | +40.5% | 0.01% | -35.7% |
| Q2 2021 | $162,000 | +3.8% | 30,596 | +31.9% | 0.01% | +16.7% |
| Q1 2021 | $156,000 | +13.0% | 23,196 | +13.7% | 0.01% | 0.0% |
| Q4 2020 | $138,000 | -0.7% | 20,396 | +9.7% | 0.01% | -52.0% |
| Q3 2020 | $139,000 | -1.4% | 18,596 | +38.3% | 0.02% | -7.4% |
| Q2 2020 | $141,000 | -4.7% | 13,450 | -19.9% | 0.03% | -15.6% |
| Q1 2020 | $148,000 | +94.7% | 16,800 | -18.3% | 0.03% | +113.3% |
| Q4 2019 | $76,000 | +43.4% | 20,563 | +46.9% | 0.02% | +50.0% |
| Q3 2019 | $53,000 | -36.1% | 14,000 | +7.7% | 0.01% | -28.6% |
| Q2 2019 | $83,000 | -1.2% | 13,000 | +28.7% | 0.01% | -6.7% |
| Q1 2019 | $84,000 | – | 10,100 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,704,849 | $9,036,000 | 6.19% |
| RA Capital Management | 10,874,613 | $57,635,000 | 0.92% |
| Mesirow Financial Investment Management, Inc. | 42,104 | $223,000 | 0.57% |
| ACT CAPITAL MANAGEMENT, LLC | 190,000 | $1,007,000 | 0.52% |
| Samsara BioCapital, LLC | 601,162 | $3,186,000 | 0.39% |
| Orbimed Advisors | 5,465,030 | $28,965,000 | 0.29% |
| ALGERT GLOBAL LLC | 72,490 | $384,000 | 0.13% |
| Knights of Columbus Asset Advisors LLC | 236,257 | $1,252,000 | 0.12% |
| Bridgefront Capital, LLC | 47,569 | $252,000 | 0.10% |
| Matisse Capital | 56,100 | $297,000 | 0.09% |